SEC Form 4 · accession 0001161697-26-000132
CATALYST PHARMACEUTICALS, INC. · CPRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
William T. Andrews
Officer — Chief Medical Officer
Period of report
Jun 3, 2026
Accepted (ET)
Jun 5, 2026 · 5:00 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001369568
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $0.001 per shareF1 | Jun 3, 2026 | M | 3,052 | — | A | 3,052 | D | |
| Common Stock, par value $0.001 per shareF2 | Jun 3, 2026 | F | 743 | — | D | 2,309 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F3,F4 | — | Jun 3, 2025 | M | 3,052 | D | — | — | Common Stock | 3,052 | 240,195 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting.
- F2Shares withheld by the Registrant to satisfy applicable withholding taxes upon vesting of restricted common stock.
- F3Derivative securities vest in equal tranches, 1/5th each on June 2, 2026, 2027, 2028, 2029, and 2030.
- F4Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The first tranche of shares was delivered on June 3, 2026.